AJP - Lung AJP: Heart and Circulatory Physiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Lung Cell Mol Physiol 297: L658-L665, 2009. First published July 17, 2009; doi:10.1152/ajplung.00189.2009
1040-0605/09 $8.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
297/4/L658    most recent
00189.2009v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Weissmann, N.
Right arrow Articles by Schermuly, R. T.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Weissmann, N.
Right arrow Articles by Schermuly, R. T.

The soluble guanylate cyclase activator HMR1766 reverses hypoxia-induced experimental pulmonary hypertension in mice

Norbert Weissmann,1 Sascha Hackemack,1 Bhola Kumar Dahal,1 Soni Savai Pullamsetti,1 Rajkumar Savai,1 Manish Mittal,1 Beate Fuchs,1 Thomas Medebach,1 Rio Dumitrascu,1 Martin van Eickels,2 Hossein Ardeschir Ghofrani,1 Werner Seeger,1 Friedrich Grimminger,1 and Ralph Theo Schermuly1

1University of Giessen Lung Center Medical Clinic II/V, Giessen; and ; 2Sanofi-Aventis Deutschland, Frankfurt am Main, Germany

Submitted 3 June 2009 ; accepted in final form 16 June 2009

Severe pulmonary hypertension (PH) is a disabling disease with high mortality, characterized by pulmonary vascular remodeling and right heart hypertrophy. In mice with PH induced by chronic hypoxia, we examined the acute and chronic effects of the soluble guanylate cyclase (sGC) activator HMR1766 on hemodynamics and pulmonary vascular remodeling. In isolated perfused mouse lungs from control animals, HMR1766 dose-dependently inhibited the pressor response of acute hypoxia. This dose-response curve was shifted leftward when the effects of HMR1766 were investigated in isolated lungs from chronic hypoxic animals for 21 days at 10% oxygen. Mice exposed for 21 or 35 days to chronic hypoxia developed PH, right heart hypertrophy, and pulmonary vascular remodeling. Treatment with HMR1766 (10 mg·kg–1·day–1), after full establishment of PH from day 21 to day 35, significantly reduced PH, as measured continuously by telemetry. In addition, right ventricular (RV) hypertrophy and structural remodeling of the lung vasculature were reduced. Pharmacological activation of oxidized sGC partially reverses hemodynamic and structural changes in chronic hypoxia-induced experimental PH.

vascular remodeling; telemetry


Address for reprint requests and other correspondence: R. Schermuly, Univ. of Giessen Lung Center Medical Clinic II/V, Klinikstr. 36, 35392 Giessen, Germany (e-mail: ralph.schermuly{at}uglc.de).






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2009 by the American Physiological Society.